KIF11 and urinary bladder cancer: S(MeO)TLC, as a novel Eg5 inhibitor, exhibited significant anticancer efficacy in gemcitabine resistant bladder cancer cell lines both in vitro and in vivo, and may provide a new therapeutic option to overcome chemoresistance in bladder cancer.